CORT - Corcept Therapeutics Incorporated
NASDAQ
->
Healthcare
->
Biotechnology
Menlo Park,
United States
Type: Equity
CORT price evolution
CORT
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $128.59 | $149.75 | $135.55 | |
| Short term investments | $344.57 | $261.01 | $232.67 | |
| Net receivables | $59.72 | $53.84 | $61.52 | $41.12 |
| Inventory | $8.05 | $16.8 | $15.04 | $15.97 |
| Total current assets | $466.98 | $560.85 | $503.37 | $458.64 |
| Long term investments | $19.32 | $40.28 | $57.18 | |
| Property, plant & equipment | $8.43 | $7.16 | $0.19 | $0.32 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $153.71 | $152.57 | $162.88 | |
| Total investments | $363.88 | $301.29 | $289.85 | |
| Total assets | $784.26 | $714.55 | $655.93 | $621.52 |
| Current liabilities | ||||
| Accounts payable | $18.58 | $19.48 | $12.56 | $17.4 |
| Deferred revenue | ||||
| Short long term debt | $0.04 | $0.08 | $0.15 | |
| Total current liabilities | $126.22 | $100.75 | $97.2 | $104.5 |
| Long term debt | $5.63 | |||
| Total noncurrent liabilities | $17.56 | $10.87 | $10.31 | |
| Total debt | $5.67 | $0.08 | $0.15 | |
| Total liabilities | $145.42 | $118.31 | $108.07 | $114.81 |
| Shareholders' equity | ||||
| Retained earnings | $512.99 | $465.78 | $430.29 | $402.53 |
| Other shareholder equity | $1.57 | $0.08 | $0.26 | $0.61 |
| Total shareholder equity | $596.24 | $547.86 | $506.7 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $135.55 | $66.33 | $77.62 | $76.19 |
| Short term investments | $232.67 | $365.34 | $145.92 | $364.51 |
| Net receivables | $41.12 | $31.06 | $27.63 | $26.2 |
| Inventory | $15.97 | $6.1 | $17.95 | $21.16 |
| Total current assets | $458.64 | $499.25 | $266.46 | $478.5 |
| Long term investments | $57.18 | $4.95 | $112.28 | $36.2 |
| Property, plant & equipment | $0.32 | $1.78 | $1.52 | $4.18 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $162.88 | $84.18 | $157.29 | $93.23 |
| Total investments | $289.85 | $370.29 | $258.19 | $400.7 |
| Total assets | $621.52 | $583.43 | $423.76 | $571.73 |
| Current liabilities | ||||
| Accounts payable | $17.4 | $11.98 | $6.91 | $10.55 |
| Deferred revenue | ||||
| Short long term debt | $0.15 | $1.14 | $0.53 | $2.05 |
| Total current liabilities | $104.5 | $72.49 | $47.54 | $47.49 |
| Long term debt | $0.5 | |||
| Total noncurrent liabilities | $10.31 | $9.1 | $0.41 | $0.9 |
| Total debt | $0.15 | $1.14 | $0.53 | $2.55 |
| Total liabilities | $114.81 | $81.59 | $47.95 | $48.39 |
| Shareholders' equity | ||||
| Retained earnings | $402.53 | $296.39 | $194.97 | $82.46 |
| Other shareholder equity | $0.61 | -$0.87 | -$0.23 | $0.41 |
| Total shareholder equity | $506.7 | $501.84 | $375.81 | $523.34 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $182.55 | $163.8 | $146.81 | $135.41 |
| Cost of revenue | $2.52 | $2.54 | $1.88 | |
| Gross Profit | $179.68 | $161.27 | $144.27 | $133.53 |
| Operating activities | ||||
| Research & development | $58.74 | $58.51 | $54.71 | |
| Selling, general & administrative | $66.94 | $56.27 | $47.15 | |
| Total operating expenses | $133.08 | $125.68 | $114.77 | $101.86 |
| Operating income | $35.59 | $29.5 | $31.67 | |
| Income from continuing operations | ||||
| EBIT | $35.22 | $29.25 | $31.46 | |
| Income tax expense | $5.73 | $6.11 | $7.23 | $5.45 |
| Interest expense | $6.34 | -$6 | -$5.49 | -$5.14 |
| Net income | ||||
| Net income | $47.21 | $35.12 | $27.51 | $31.14 |
| Income (for common shares) | $35.12 | $27.51 | $31.14 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $482.38 | $401.86 | $365.98 | $353.87 |
| Cost of revenue | $6.48 | $5.38 | $5.28 | $5.58 |
| Gross Profit | $475.89 | $396.47 | $360.7 | $348.29 |
| Operating activities | ||||
| Research & development | $184.35 | $130.99 | $113.86 | $114.76 |
| Selling, general & administrative | $184.26 | $152.85 | $122.36 | $105.33 |
| Total operating expenses | $368.61 | $283.84 | $236.22 | $220.09 |
| Operating income | $107.28 | $112.63 | $124.48 | $128.2 |
| Income from continuing operations | ||||
| EBIT | $106.64 | $112.5 | $124.48 | $128.2 |
| Income tax expense | $18.42 | $14.77 | $12.49 | $25.59 |
| Interest expense | -$17.27 | -$3.56 | -$0.53 | -$3.4 |
| Net income | ||||
| Net income | $105.5 | $101.29 | $112.51 | $106.01 |
| Income (for common shares) | $105.5 | $101.29 | $112.51 | $106.01 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $35.12 | $27.51 | $31.14 | |
| Operating activities | ||||
| Depreciation | $0.2 | $0.18 | $0.63 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $15.21 | $13.25 | $13.06 | |
| Total cash flows from operations | $41.18 | $23.76 | $5.89 | |
| Investing activities | ||||
| Capital expenditures | -$0.42 | |||
| Investments | -$59.78 | -$9.01 | $17.1 | |
| Total cash flows from investing | -$113.24 | -$60.19 | -$9.01 | $17.1 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$2.15 | -$0.54 | $0.77 | |
| Net borrowings | ||||
| Total cash flows from financing | -$23.79 | -$2.15 | -$0.54 | $0.77 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $1.74 | -$21.16 | $14.2 | $23.75 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $105.5 | $101.29 | $112.51 | $106.01 |
| Operating activities | ||||
| Depreciation | $2.36 | $2.97 | $3.07 | $2.24 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $48.94 | $42.44 | $42.93 | $33.54 |
| Total cash flows from operations | $127.04 | $120.32 | $167.89 | $151.97 |
| Investing activities | ||||
| Capital expenditures | -$0.14 | -$0.41 | -$0.47 | -$1.24 |
| Investments | $91.05 | -$113.91 | $136.59 | -$118.03 |
| Total cash flows from investing | $90.91 | -$114.33 | $136.13 | -$119.26 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$148.72 | -$17.28 | -$302.59 | $12.21 |
| Net borrowings | ||||
| Total cash flows from financing | -$148.72 | -$17.28 | -$302.59 | $12.21 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $69.22 | -$11.29 | $1.43 | $44.92 |
News
Fundamentals
| Market cap | $8.74B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 104.40M |
| Revenue | $628.55M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $140.99M |
| Revenue Q/Q | 47.69% |
| Revenue Y/Y | 39.67% |
| P/E ratio | 62.02 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 13.91 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | $1.35 |
|---|---|
| ROA | 20.31% |
| ROE | N/A |
| Debt/Equity | 0.23 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.70 |
| Quick ratio | 3.64 |